Chembio Diagnostics Appoints Industry Leader David Bespalko to its Board of Directors
March 08 2021 - 8:00AM
Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading
point-of-care diagnostic company focused on infectious diseases,
today announced the appointment of David Bespalko to the Company’s
Board of Directors, effective upon his election on March 4, 2021.
Mr. Bespalko brings over 35 years of leadership experience in
the global in vitro diagnostics market. Most recently he was Group
Vice President, Global Commercial Operations Specialty Diagnostics
Group at Thermo Fisher Scientific, which he joined in 2011 as
President of Fisher Healthcare. During his tenure there, Mr.
Bespalko held additional roles such as President of the Global
Anatomical Pathology Division. Previously, Mr. Bespalko was
Corporate Vice President, North America Commercial Operations at
Beckman Coulter. His diagnostics career began in Canada with
commercial and general management roles at Baxter Healthcare and
Dade Behring. Mr. Bespalko now manages his own consulting firm,
BMC, helping early-stage companies and providing executive
mentorship.
Also on March 4, 2021, Dr. Mary Lake Polan informed
the Board of Directors that she would not stand for reelection to
the Board at the Company’s 2021 Annual Meeting of Shareholders.
“We are delighted to welcome David to the Board of
Directors,” said Katherine L. Davis, Chair of Chembio's Board of
Directors. “Given David’s extensive network and experience in the
industry, he will add valuable insight to help maximize the value
of our DPP platform in the market. We look forward to his
collaboration and contributions. We also would like to thank Dr.
Polan for her service and leadership throughout her tenure and wish
her well in her future endeavors.”
“I am excited about the opportunity to work with
the Chembio team because they have an advanced point-of-care
technology and a tremendous opportunity to provide value across
decentralized settings in the healthcare landscape,” said Mr.
Bespalko. “I am thrilled to join an organization whose mission
aligns with my background, focused on expanding and scaling
operations to enable greater access to diagnostic testing.”
About the DPP Rapid Test
PlatformChembio’s proprietary DPP technology platform
provides high-quality, rapid diagnostic results in 15 to 20 minutes
using a small drop of blood from the fingertip or alternative
samples. Through advanced multiplexing, the DPP platform can detect
up to eight, distinct test results from a single patient sample,
delivering greater clinical value than other rapid tests. For
certain applications, Chembio’s easy-to-use, highly portable,
battery-operated DPP Micro Reader optical analyzer then reports
accurate results in approximately 15 seconds, making it well-suited
for decentralized testing where real-time results enable patients
to be clinically assessed while they are still on-site. Objective
results produced by the DPP Micro Reader reduce the possibility of
the types of human error that can be experienced in the visual
interpretations required by many rapid tests.
Chembio’s portfolio of DPP-based point-of-care
tests with FDA regulatory approvals include the DPP HIV-Syphilis
System (PMA approved), DPP HIV 1/2 Assay (PMA approved and CLIA
waived), DPP Zika IgM System (510(k)), and DPP Ebola Antigen System
(EUA). Additionally, DPP-based tests have received regulatory
approvals from the World Health Organization, CE-Mark, Agência
Nacional de Vigilância Sanitária (ANVISA), and other global
organizations, where they aid in the detection and diagnosis of
several other critical diseases and conditions.
All DPP tests are developed and manufactured in the
United States and are the subject of a range of domestic and global
patents and patents pending.
About Chembio DiagnosticsChembio
is a leading point-of-care diagnostics company focused on detecting
and diagnosing infectious diseases, including COVID-19, sexually
transmitted disease, and fever and tropical disease. Coupled with
Chembio’s extensive scientific expertise, its novel DPP technology
offers broad market applications beyond infectious disease.
Chembio’s products are sold globally, directly and through
distributors, to hospitals and clinics, physician offices, clinical
laboratories, public health organizations, government agencies, and
consumers. Learn more at www.chembio.com.
DPP is Chembio’s registered trademark, and the Chembio logo is
Chembio’s trademark. For convenience, these trademarks appear in
this release without ® or ™ symbols, but that practice does not
mean that Chembio will not assert, to the fullest extent under
applicable law, its rights to the trademark.
Contact:Philip TaylorGilmartin Group(415)
937-5406investor@chembio.com
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Sep 2023 to Sep 2024